{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T07:44:51Z","timestamp":1782719091177,"version":"3.54.5"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,28]]},"DOI":"10.7759\/cureus.111696","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T06:51:24Z","timestamp":1782715884000},"source":"Crossref","is-referenced-by-count":0,"title":["Aseptic Meningitis With Multiple Cranial Nerve Symptoms Induced by Atezolizumab for Lung Adenocarcinoma: A Case Report"],"prefix":"10.7759","author":[{"given":"Satsuki","family":"Mikoshiba-Takahashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiki","family":"Matsubayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiatsu","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasumi","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yamana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Kamimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104595","article-title":"Central nervous system complications of immune checkpoint inhibitors: a comprehensive review","volume":"206","author":"Lopes S","year":"2025","unstructured":"Lopes S, Pabst L, Bahougne T, et al.. Central nervous system complications of immune checkpoint inhibitors: a comprehensive review. Crit Rev Oncol Hematol. 2025, 206:104595. 10.1016\/j.critrevonc.2024.104595","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12660-2","article-title":"Immune checkpoint inhibitors-associated cranial nerves involvement: a systematic literature review on 136 patients","volume":"271","author":"Pichon S","year":"2024","unstructured":"Pichon S, Aigrain P, Lacombe C, et al.. Immune checkpoint inhibitors-associated cranial nerves involvement: a systematic literature review on 136 patients. J Neurol. 2024, 271:6514-25. 10.1007\/s00415-024-12660-2","journal-title":"J Neurol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1177\/20420986211004745","article-title":"Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative review","volume":"12","author":"Thouvenin L","year":"2021","unstructured":"Thouvenin L, Olivier T, Banna G, Addeo A, Friedlaender A. Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative review. Ther Adv Drug Saf. 2021, 12:20420986211004745. 10.1177\/20420986211004745","journal-title":"Ther Adv Drug Saf"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/1756286418799864","article-title":"Neurological complications of immune checkpoint inhibitors: what happens when you 'take the brakes off' the immune system","volume":"11","author":"Dalakas MC","year":"2018","unstructured":"Dalakas MC. Neurological complications of immune checkpoint inhibitors: what happens when you 'take the brakes off' the immune system. Ther Adv Neurol Disord. 2018, 11:1756286418799864. 10.1177\/1756286418799864","journal-title":"Ther Adv Neurol Disord"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.774170","article-title":"Neurologic toxicity of immune checkpoint inhibitors: a review of literature","volume":"13","author":"Albarr\u00e1n V","year":"2022","unstructured":"Albarr\u00e1n V, Chamorro J, Rosero DI, Saavedra C, Soria A, Carrato A, Gajate P. Neurologic toxicity of immune checkpoint inhibitors: a review of literature. Front Pharmacol. 2022, 13:774170. 10.3389\/fphar.2022.774170","journal-title":"Front Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1738382","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"19","author":"Haugh AM","year":"2020","unstructured":"Haugh AM, Probasco JC, Johnson DB. Neurologic complications of immune checkpoint inhibitors. Expert Opin Drug Saf. 2020, 19:479-88. 10.1080\/14740338.2020.1738382","journal-title":"Expert Opin Drug Saf"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer JR","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018, 36:1714-68. 10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011795","article-title":"Neurologic adverse events of immune checkpoint inhibitors: a systematic review","volume":"96","author":"Marini A","year":"2021","unstructured":"Marini A, Bernardini A, Gigli GL, Valente M, Mu\u00f1iz-Castrillo S, Honnorat J, Vogrig A. Neurologic adverse events of immune checkpoint inhibitors: a systematic review. Neurology. 2021, 96:754-66. 10.1212\/WNL.0000000000011795","journal-title":"Neurology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-022-03997-7","article-title":"Immune-related aseptic meningitis and strategies to manage immune checkpoint inhibitor therapy: a systematic review","volume":"157","author":"Nannini S","year":"2022","unstructured":"Nannini S, Koshenkova L, Baloglu S, Chaussemy D, No\u00ebl G, Schott R. Immune-related aseptic meningitis and strategies to manage immune checkpoint inhibitor therapy: a systematic review. J Neurooncol. 2022, 157:533-50. 10.1007\/s11060-022-03997-7","journal-title":"J Neurooncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: review of the literature","volume":"73","author":"Cuzzubbo S","year":"2017","unstructured":"Cuzzubbo S, Javeri F, Tissier M, et al.. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer. 2017, 73:1-8. 10.1016\/j.ejca.2016.12.001","journal-title":"Eur J Cancer"},{"key":"ref11","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. (2017). Accessed. 2026\/03\/07: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fnhum.2025.1443463","article-title":"Clinical characteristics, diagnosis, treatment, and prognosis of atezolizumab-induced encephalitis, aseptic meningitis or meningoencephalitis","volume":"19","author":"Yan Q","year":"2025","unstructured":"Yan Q, Hu Y, Liu X, Xia H. Clinical characteristics, diagnosis, treatment, and prognosis of atezolizumab-induced encephalitis, aseptic meningitis or meningoencephalitis. Front Hum Neurosci. 2025, 19:1443463. 10.3389\/fnhum.2025.1443463","journal-title":"Front Hum Neurosci"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1590\/0004-282X-ANP-2022-S116","article-title":"Neurologic adverse events of cancer immunotherapy","volume":"80","author":"Brito MH","year":"2022","unstructured":"Brito MH. Neurologic adverse events of cancer immunotherapy. Arq Neuropsiquiatr. 2022, 80:270-80. 10.1590\/0004-282X-ANP-2022-S116","journal-title":"Arq Neuropsiquiatr"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011340","article-title":"Cranial nerve disorders associated with immune checkpoint inhibitors","volume":"96","author":"Vogrig A","year":"2021","unstructured":"Vogrig A, Mu\u00f1iz-Castrillo S, Joubert B, et al.. Cranial nerve disorders associated with immune checkpoint inhibitors. Neurology. 2021, 96:e866-75. 10.1212\/WNL.0000000000011340","journal-title":"Neurology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.62.11.1714","article-title":"Multiple cranial nerve palsies: analysis of 979 cases","volume":"62","author":"Keane JR","year":"2005","unstructured":"Keane JR. Multiple cranial nerve palsies: analysis of 979 cases. Arch Neurol. 2005, 62:1714-7. 10.1001\/archneur.62.11.1714","journal-title":"Arch Neurol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/474155-aseptic-meningitis-with-multiple-cranial-nerve-symptoms-induced-by-atezolizumab-for-lung-adenocarcinoma-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T06:51:30Z","timestamp":1782715890000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/474155-aseptic-meningitis-with-multiple-cranial-nerve-symptoms-induced-by-atezolizumab-for-lung-adenocarcinoma-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,28]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.111696","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,28]]}}}